Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: Results from intergroup trial N9741

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8263-8269

  Fuchs, Charles S ^a,b   Goldberg, Richard M ^c   Sargent, Daniel J ^d   Meyerhardt, Jeffrey A ^a,b   Wolpin, Brian M ^a,b   Green, Erin M ^d   Pitot, Henry C ^e   Pollak, Michael ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d North Central Cancer Treatment Group Rochester   (United States)

^e MAYO CLINIC   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; BIOLOGICAL MARKER; IGFBP3 PROTEIN, HUMAN; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; COLORECTAL TUMOR; PATHOLOGY;

BIOLOGICAL MARKERS; BODY MASS INDEX; C-PEPTIDE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; NEOPLASM METASTASIS;

EID: 58149359607     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0480     Document Type: Article

References (47)

1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
2. TaoY, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007;4:591 -602.
3. Firth SM, Baxter RC. Cellular actions of the insulinlike growth factor binding proteins. Endocr Rev 2002;23:824-54.
4. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β 1 on programmed cell death through a p53- and IGF-in- dependent mechanism. J Biol Chem 1997;272: 12181 -8.
5. Williams AC, Smartt H, AM HZ, Macfarlane M, ParaskevaC,CollardTJ. Insulin-likegrowth factorbind- ing protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-κB. Cell Death Differ 2007;14:137-45.
6. AM HZ, Collard TJ, Malik K, Hicks DJ, Paraskeva C, Williams AC. Induction of apoptosis by the 16-kDa amino-terminal fragment of the insulin-like growth factor binding protein 3 in human colonic carcinoma cells. Int J Oncol 2006;29:1279-86.
7. Kirman I, Poltoratskaia N, Sylla P,Whelan RL. Insulinlike growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery 2004;136: 205-9.
8. Jenkins PJ, Khalaf S, Ogunkolade W, et al. Differential expression of IGF-binding protein-3 in normal andma- lignant colon and its influence on apoptosis. Endocr Relat Cancer 2005;12:891 -901.
9. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
10. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF- binding protein-3. J Natl Cancer Inst1999;91:620-5.
11. Ma J, Giovannucci E, Pollak M, et al. Aprospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-53.
12. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002;50: 642-6.
13. Probst-Hensch NM,Yuan JM, Stanczyk FZ, Gao YT, Ross RK,Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001;85:1695-9.
14. Kaaks R,Toniolo P, AkhmedkhanovA, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF- binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592 -600.
15. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol BiomarkersPrev2000;9: 345-9.
16. Manousos O, SouglakosJ, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-7.
17. Hunt KJ,Toniolo P, Akhmedkhanov A, et al. Insulinlike growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 2002;11: 901 -5.
18. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344-50.
19. Jenab M, Riboli E, Cleveland RJ, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121:368-76.
20. Otani T, Iwasaki M, Sasazuki S, InoueM,TsuganeS. Plasma C-peptide, insulin-like growth factor-I, insulinlike growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer 2007;120:2007 -12.
21. Wei EK, Ma J, Pollak MN, et al. Aprospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colo- rectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005;14:850-5.
22. Goldberg RM, Sargent DJ, Morton RF, et al. Arandomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23 -30.
23. Meyerhardt JA, Sloan JA, Sargent DJ, et al. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Bio-markers Prev 2005;14:1402 -10.
24. Harris TG, Strickler HD,Yu H, et al. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res 2006;16: 86 -92.
25. Giovannucci E, Pollak M, Liu Y, et al. Nutritionalpre- dictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9.
26. Giovannucci E, Rimm EB, Liu Y,Willett WC. Height, predictors of C-peptide and cancer risk in men. Int J Epidemiol 2004;33:217-25.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457 -81.
28. Cox DR. Regression models and life-tables [with discussion]. J Royal Stat Soc B 1972;34:187-220.
29. Cohen J. Statistical power analysis for behavioral sciences. New Jersey: Lawrence Erlbaum Associates; 1988.
30. Kleinbaum D, Kupper L, Nizam A, Muller K. Applied regression analysis and other multivariable methods. Pacific Grove (CA): Duxbury Press; 1997.
31. Haydon AM, Macinnis RJ, English DR, Morris H, Giles GG. Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut 2006;55:689-94.
32. Rechler MM. Editorial: Growth inhibition by insulinlike growth factor (IGF) binding protein-3-what's igf got to do with it? Endocrinology 1997;138:2645-7.
33. Cohen P. Insulin-like growth factor binding protein- 3: insulin-like growth factor independence comes of age. Endocrinology 2006;147:2109 -11.
34. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215 -44.
35. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001;22:818-35.
36. Dean DJ, Gazdag AC, Wetter TJ, Cartee GD.Comparison of the effects of 20 days and 15 months of calorie restriction on male Fischer 344 rats. Aging Milano 1998;10:303-7.
37. Zuniga-Guajardo S,Garfinke lPE, Zinman B. Changes in insulin sensitivity and clearance in anorexia nervosa. Metabolism 1986;35:1096 -100.
38. Juul A, Bang P, Herte lNT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-52.
39. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low Serum Insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002;106:939 -44.
40. Carroll PV, Littlewood R,Weissberger AJ, et al. The effects of two doses of replacement growth hormone on the biochemical, body composition and psychological profiles of growth hormone-deficient adults. Eur J Endocrinol 1997;137:146-53.
41. Soares CN, Musolino NR, Cunha Neto M, et al. Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults. A placebo-controlled trial. Arq Neuropsiquiatr1999;57: 182-9.
42. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study. Neurology 1997;49:1621 -30.
43. Lee PD, Pivarnik JM, Bukar JG, et al. Arandomized, placebo-controlled trial of combined insulin-like growth factor I and lowdose growth hormonetherapy for wasting associated with human immunodeficiency virus infection [published erratum appears in J Clin Endocrinol Metab 1996;81:3696]. J Clin Endocrinol Metab 1996;81:2968-75.
44. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapyin AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med1996;125:865 -72.
45. Rajpathak SN, McGinn AP, Strickler HD, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 2008;18:166-73.
46. Holdaway IM, Mason BH, Lethaby AE, et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg 2003;73:905.
47. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465 -8.